Prespecified secondary pooled analysis of 3 placebo-controlled trials (18,991 patients with CKD and type 2 diabetes or HFmrEF/HFpEF): finerenone reduced sudden death vs placebo (HR 0.81; 95% CI 0.67–0.98), consistently across trials, over median 2.9 years.
Secondary analysisn = 18,991
Foà et al. Effects of Finerenone on Sudden Death Across the Cardio-Kidney-Metabolic Landscape: A FINE-HEART Analysis